ArticleCureus2026
From Unicentric Castleman Disease to Lymphoma: A Rare Case Highlighting a Diagnostic and Therapeutic Challenge.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Unicentric Castleman disease (UCD) is a rare lymphoproliferative disorder treated with surgical resection. However, its association with lymphoma, particularly nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), is rare and not well characterized. We report a case highlighting the potential for malignant transformation in an otherwise asymptomatic patient. The patient was a 28-year-old male with a history of UCD (hyaline vascular type) in the mediastinum who presented for routine follow-up of previously enlarged lymph nodes. Surveillance chest CT revealed a new posterior mediastinal lymph node. He was asymptomatic, with an unremarkable examination and laboratory studies except for a shortened activated partial thromboplastin time (aPTT). Histopathology showed lymphocyte-predominant (LP) cells with immunophenotypic positivity for CD20, BCL-6, and epithelial membrane antigen (EMA), consistent with NLPHL. Due to the diagnostic complexity, he was treated as having a non-Hodgkin lymphoma-like entity with R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) Although UCD is typically considered curable with surgical resection, this case demonstrates that, in rare cases, it can progress to lymphoma, specifically NLPHL. The clinical course was asymptomatic, highlighting the variability in presentation and the need for a high index of suspicion in patients with recurrent mediastinal masses. Furthermore, the sequential development of UCD and NLPHL underscores the biological complexity of lymphoproliferative disorders and the potential overlap in immunophenotypic features. This case illustrates that even localized forms of UCD may be associated with subsequent lymphoid malignancy, emphasizing the importance of continuous clinical surveillance and a multidisciplinary approach to management. Histopathological reassessment of new lesions is crucial, and clinicians should consider the possibility of malignant transformation in patients with a history of UCD to ensure accurate diagnosis and timely treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.